MedTrace Logo

A Study of Guselkumab in Participants With Crohn's Disease and Ulcerative Colitis

NCT07606339 · Status: NOT_YET_RECRUITING · Type: OBSERVATIONAL · Enrollment: 35

Last updated 2026-05-26

No results posted yet for this study

Summary

The purpose of this study is to evaluate how long a participant keeps taking guselkumab or continues with their treatment plan without stopping (treatment persistence) in participants with moderate to severe Crohn's disease (CD) or ulcerative colitis (UC) in real-world setting. CD and UC are inflammatory bowel diseases, a group of inflammatory conditions of the colon and small intestine.

Conditions

  • Crohn Disease
  • Colitis, Ulcerative

Sponsors & Collaborators

  • Janssen-Cilag Pharma GmbH

    lead INDUSTRY

Principal Investigators

  • Janssen-Cilag Pharma GmbH Clinical Trial · Janssen-Cilag Pharma GmbH

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-06-15
Primary Completion
2029-06-15
Completion
2029-06-15

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07606339 on ClinicalTrials.gov